{"protocolSection": {"identificationModule": {"nctId": "NCT00819741", "orgStudyIdInfo": {"id": "AGEE-3705"}, "organization": {"fullName": "Novo Nordisk A/S", "class": "INDUSTRY"}, "briefTitle": "Comparison of the Blood Sugar Lowering Effect Between Repaglinide Plus Metformin and Repaglinide Alone in Type 2 Diabetics Not Previously Treated With Oral Sugar-lowering Drugs", "officialTitle": "A 16-week, Open-label, Multicentre, Randomised, Parallel Study to Evaluate Efficacy and Safety of Repaglinide and Metformin Combination Therapy Compared to Repaglinide Monotherapy in Chinese OAD Naive Type 2 Diabetic Patients"}, "statusModule": {"statusVerifiedDate": "2016-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-02"}, "primaryCompletionDateStruct": {"date": "2009-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-01-08", "studyFirstSubmitQcDate": "2009-01-08", "studyFirstPostDateStruct": {"date": "2009-01-09", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-11-05", "resultsFirstSubmitQcDate": "2010-11-05", "resultsFirstPostDateStruct": {"date": "2010-12-08", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-12-19", "lastUpdatePostDateStruct": {"date": "2017-02-10", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novo Nordisk A/S", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This trial is conducted in Asia. The aim of this clinical trial is to investigate the blood sugar lowering effect of repaglinide plus metformin as initial treatment compared to repaglinide alone in Chinese subjects with type 2 diabetes having an HbA1c (glycosylated haemoglobin A1c) over 8.5 % and who never have taken oral sugar-lowering drugs before. The associated unfavourable events including low blood sugar episodes between the two treatments are also compared."}, "conditionsModule": {"conditions": ["Diabetes", "Diabetes Mellitus, Type 2"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 433, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Repaglinide + metformin", "type": "EXPERIMENTAL", "description": "Initial dose of repaglinide 1mg plus metformin 500mg once daily. During the dose titration period of 6 weeks, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily.", "interventionNames": ["Drug: repaglinide", "Drug: metformin"]}, {"label": "Repaglinide", "type": "ACTIVE_COMPARATOR", "description": "Initial dose of repaglinide 1 mg three times daily. During the dose titration period of 6 weeks, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg three times daily.", "interventionNames": ["Drug: repaglinide"]}], "interventions": [{"type": "DRUG", "name": "repaglinide", "description": "The dose was started from repaglinide 1 mg plus metformin 500 mg once daily. During the dose titration period, the dose could be titrated up to repaglinide 4 mg and metformin 500mg three times daily, according to fasting glucose. the minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily", "armGroupLabels": ["Repaglinide + metformin"]}, {"type": "DRUG", "name": "metformin", "description": "The dose was started from repaglinide 1 mg plus metformin 500 mg once daily. During the dose titration period, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose. the minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily", "armGroupLabels": ["Repaglinide + metformin"]}, {"type": "DRUG", "name": "repaglinide", "description": "The dose was started from repaglinide 1 mg three times daily. During the dose titration period, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose.", "armGroupLabels": ["Repaglinide"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Glycosylated Haemoglobin A1c (HbA1c)", "description": "Calculated as an estimate of the mean change in HbA1c after 16 weeks of treatment.", "timeFrame": "week -2 (screening), week 16"}], "secondaryOutcomes": [{"measure": "Change in Fasting Plasma Glucose", "description": "Calculated as an estimate of the mean change in fasting plasma glucose after 16 weeks of treatment.", "timeFrame": "week 0, week 16"}, {"measure": "Change in 2-hour Postprandial Plasma Glucose", "description": "Calculated as an estimate of the mean change in 2-hour postprandial plasma glucose following a standard test meal after 16 weeks of treatment", "timeFrame": "Week 0, week 16"}, {"measure": "Change in 7-point Plasma Glucose Profile", "description": "Calculated as an estimate of the mean change in 7-point (before breakfast, 2 hours after breakfast, before lunch, 2 hours after lunch, before dinner, 2 hours after dinner, bedtime) plasma glucose profile after 16 weeks of treatment.", "timeFrame": "Week 0, week 16"}, {"measure": "Change in Fasting Serum Insulin", "description": "Calculated as an estimate of the mean change in fasting serum insulin after 16 weeks of treatment.", "timeFrame": "Week 0, week 16"}, {"measure": "Change in 2-hour Postprandial Serum Insulin", "description": "Calculated as an estimate of the mean change in 2-hour postprandial serum insulin after 16 weeks of treatment.", "timeFrame": "Week 0, week 16"}, {"measure": "Change in Fasting Serum C-peptide", "description": "Calculated as an estimate of the mean change in fasting serum C-peptide after 16 weeks of treatment", "timeFrame": "Week 0, week 16"}, {"measure": "Change in 2-hour Postprandial Serum C-peptide", "description": "Calculated as an estimate of the mean change in 2-hour postprandial serum C-peptide after 16 weeks of treatment", "timeFrame": "Week 0, week 16"}, {"measure": "Hypoglycaemic Episodes", "description": "Number of hypoglycaemic episodes from Week 0 to Week 16, defined as major, minor or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.", "timeFrame": "Weeks 0-16"}, {"measure": "Change in Blood Pressure", "description": "Calculated as the mean change in diastolic and systolic blood pressure after 16 weeks of treatment", "timeFrame": "Week 0, week 16"}, {"measure": "Physical Examinations", "description": "The number of subjects having a physical examination event that changed from 'Normal' or 'Abnormal, not clinically significant' to 'Abnormal, clinically significant'. Physical examination included cardiovascular system, respiratory system, musculoskeletal system, nervous system and abdomen.", "timeFrame": "Week -2, week 16"}, {"measure": "ECG (ElectroCardioGram)", "description": "The number of subjects having a electrocardiogram (ECG) that changed from 'Normal' or 'Abnormal, not clinically significant' to 'Abnormal, clinically significant'. 'Abnormal, Clinically significant' is an abnormality that suggests a disease and/or organ toxicity and is of a severity, which requires active management.", "timeFrame": "Week -2, week 16"}, {"measure": "Biochemistry: Alanine Aminotransferase (ALAT)", "description": "The number of subjects having a change in Alanine Aminotransferase (ALAT) from 'Normal' or 'Abnormal, not clinically significant' to 'Abnormal, clinically significant'. 'Abnormal, Clinically significant' is an abnormality that suggests a disease and/or organ toxicity and is of a severity, which requires active management.", "timeFrame": "Week -2, week 16"}, {"measure": "Biochemistry: Alanine Aminotransferase (ASAT)", "description": "The number of subjects having a change in Aspartate Aminotransferase (ASAT) from 'Normal' or 'Abnormal, not clinically significant' to 'Abnormal, clinically significant'. 'Abnormal, Clinically significant' is an abnormality that suggests a disease and/or organ toxicity and is of a severity, which requires active management.", "timeFrame": "Week -2, week 16"}, {"measure": "Haematology: Haemoglobin", "description": "Haemoglobin was measured. The number of subjects having a change in Haemoglobin measurement from 'Normal' or 'Abnormal, not clinically significant' to 'Abnormal, clinically significant' 'Abnormal, Clinically significant' is an abnormality that suggests a disease and/or organ toxicity and is of a severity, which requires active management.", "timeFrame": "Week -2, week 16"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosed with type 2 diabetes\n* Never taken oral antidiabetic drugs before\n* HbA1c greater than 8.5 %\n* BMI (Body Mass Index) less than or equal to 35 kg/m\\^2\n\nExclusion Criteria:\n\n* Known or suspected allergy to repaglinide, metformin, or any of the excipients in the medications\n* Taken an investigational drug in another clinical trial within 4 weeks prior to this trial\n* Impaired liver function, defined as ASAT (aspartate aminotransferase) or ALAT (alanine aminotransferase) equal to or greater than 2 times upper normal limit\n* Have a clinically significant, active disease of the gastrointestinal, pulmonary, neurological, renal, genitourinary, and haematological systems\n* Severe uncontrolled or untreated hypertension (sitting diastolic blood pressure (BP) equal to or greater than 100 mmHg or systolic BP equal to or greater than 180 mmHg)\n* Impaired renal function\n* Acute or chronic acidosis or if there are plans to have a radiographic material containing iodine\n* Have a clinically significant, active cardiovascular disease, or decompensated heart failure\n* Treatment with systemic corticosteroids within the past two months prior to screening", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Global Clinical Registry (GCR, 1452)", "affiliation": "Novo Nordisk A/S", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novo Nordisk Investigational Site", "city": "Fuzhou", "state": "Fujian", "zip": "350001", "country": "China", "geoPoint": {"lat": 26.06139, "lon": 119.30611}}, {"facility": "Novo Nordisk Investigational Site", "city": "Nanjing", "state": "Jiangsu", "zip": "210009", "country": "China", "geoPoint": {"lat": 32.06167, "lon": 118.77778}}, {"facility": "Novo Nordisk Investigational Site", "city": "Nanjing", "state": "Jiangsu", "zip": "210012", "country": "China", "geoPoint": {"lat": 32.06167, "lon": 118.77778}}, {"facility": "Novo Nordisk Investigational Site", "city": "Nanjing", "state": "Jiangsu", "zip": "210029", "country": "China", "geoPoint": {"lat": 32.06167, "lon": 118.77778}}, {"facility": "Novo Nordisk Investigational Site", "city": "Suzhou", "state": "Jiangsu", "zip": "215004", "country": "China", "geoPoint": {"lat": 31.30408, "lon": 120.59538}}, {"facility": "Novo Nordisk Investigational Site", "city": "Wuxi", "state": "Jiangsu", "zip": "214023", "country": "China", "geoPoint": {"lat": 31.56887, "lon": 120.28857}}, {"facility": "Novo Nordisk Investigational Site", "city": "Nanchang", "state": "Jiangxi", "zip": "330006", "country": "China", "geoPoint": {"lat": 28.68396, "lon": 115.85306}}, {"facility": "Novo Nordisk Investigational Site", "city": "Shanghai", "state": "Shanghai", "zip": "200001", "country": "China", "geoPoint": {"lat": 31.22222, "lon": 121.45806}}, {"facility": "Novo Nordisk Investigational Site", "city": "Shanghai", "state": "Shanghai", "zip": "200025", "country": "China", "geoPoint": {"lat": 31.22222, "lon": 121.45806}}, {"facility": "Novo Nordisk Investigational Site", "city": "Shanghai", "state": "Shanghai", "zip": "200072", "country": "China", "geoPoint": {"lat": 31.22222, "lon": 121.45806}}, {"facility": "Novo Nordisk Investigational Site", "city": "Shanghai", "state": "Shanghai", "zip": "200092", "country": "China", "geoPoint": {"lat": 31.22222, "lon": 121.45806}}, {"facility": "Novo Nordisk Investigational Site", "city": "Shanghai", "state": "Shanghai", "zip": "200120", "country": "China", "geoPoint": {"lat": 31.22222, "lon": 121.45806}}, {"facility": "Novo Nordisk Investigational Site", "city": "Hangzhou", "state": "Zhejiang", "zip": "310003", "country": "China", "geoPoint": {"lat": 30.29365, "lon": 120.16142}}, {"facility": "Novo Nordisk Investigational Site", "city": "Wenzhou", "state": "Zhejiang", "zip": "325000", "country": "China", "geoPoint": {"lat": 27.99942, "lon": 120.66682}}, {"facility": "Novo Nordisk Investigational Site", "city": "Hangzhou", "zip": "310016", "country": "China", "geoPoint": {"lat": 30.29365, "lon": 120.16142}}, {"facility": "Novo Nordisk Investigational Site", "city": "Nantong", "zip": "226001", "country": "China", "geoPoint": {"lat": 32.03028, "lon": 120.87472}}, {"facility": "Novo Nordisk Investigational Site", "city": "Shanghai", "zip": "200040", "country": "China", "geoPoint": {"lat": 31.22222, "lon": 121.45806}}]}, "referencesModule": {"references": [{"pmid": "21780853", "type": "RESULT", "citation": "Wang W, Bu R, Su Q, Liu J, Ning G. Randomized study of repaglinide alone and in combination with metformin in Chinese subjects with type 2 diabetes naive to oral antidiabetes therapy. Expert Opin Pharmacother. 2011 Dec;12(18):2791-9. doi: 10.1517/14656566.2011.602341. Epub 2011 Jul 22."}], "seeAlsoLinks": [{"label": "Clinical Trials at Novo Nordisk", "url": "http://novonordisk-trials.com"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Between screening and treatment with trial drug, subjects were assessed for eligibility and were randomised to one of two treatment arms. After start of treatment, all the subjects underwent a 6-week dose titration period followed by a 10-week maintenance period. A subgroup of 50 subjects from each treatment group was chosen.", "recruitmentDetails": "The trial was conducted at 17 sites in China.", "groups": [{"id": "FG000", "title": "Repaglinide + Metformin", "description": "Initial dose of repaglinide 1mg plus metformin 500mg once daily. During the dose titration period of 6 weeks, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily."}, {"id": "FG001", "title": "Repaglinide", "description": "Initial dose of repaglinide 1 mg three times daily. During the dose titration period of 6 weeks, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg three times daily."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "218"}, {"groupId": "FG001", "numSubjects": "215"}]}, {"type": "Exposed to Drug", "achievements": [{"groupId": "FG000", "numSubjects": "218"}, {"groupId": "FG001", "comment": "One subject after randomisation was not exposed to the treatment due to non-compliance", "numSubjects": "214"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "196"}, {"groupId": "FG001", "numSubjects": "201"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "22"}, {"groupId": "FG001", "numSubjects": "14"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Unclassified", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Reasons unknown", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Repaglinide + Metformin", "description": "Initial dose of repaglinide 1mg plus metformin 500mg once daily. During the dose titration period of 6 weeks, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily."}, {"id": "BG001", "title": "Repaglinide", "description": "Initial dose of repaglinide 1 mg three times daily. During the dose titration period of 6 weeks, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg three times daily."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "218"}, {"groupId": "BG001", "value": "214"}, {"groupId": "BG002", "value": "432"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "50.4", "spread": "9.6"}, {"groupId": "BG001", "value": "49.4", "spread": "10.0"}, {"groupId": "BG002", "value": "49.9", "spread": "10.0"}]}]}]}, {"title": "Gender", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "60"}, {"groupId": "BG001", "value": "59"}, {"groupId": "BG002", "value": "119"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "158"}, {"groupId": "BG001", "value": "155"}, {"groupId": "BG002", "value": "313"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "218"}, {"groupId": "BG001", "value": "214"}, {"groupId": "BG002", "value": "432"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "BMI", "description": "BMI (Body Mass Index)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "24.50", "spread": "2.97"}, {"groupId": "BG001", "value": "24.44", "spread": "3.05"}, {"groupId": "BG002", "value": "24.47", "spread": "3.00"}]}]}]}, {"title": "Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "68.3", "spread": "10.8"}, {"groupId": "BG001", "value": "68.2", "spread": "11.0"}, {"groupId": "BG002", "value": "68.3", "spread": "10.9"}]}]}]}, {"title": "Duration of diabetes", "description": "Number of months since dignosis", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "months", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0.14", "spread": "0.73"}, {"groupId": "BG001", "value": "0.28", "spread": "1.57"}, {"groupId": "BG002", "value": "0.21", "spread": "1.22"}]}]}]}, {"title": "HbA1c", "description": "Glycosylated haemoglobin A1c", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percentage (%) of total haemoglobin", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "10.91", "spread": "1.45"}, {"groupId": "BG001", "value": "10.73", "spread": "1.50"}, {"groupId": "BG002", "value": "10.82", "spread": "1.48"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Glycosylated Haemoglobin A1c (HbA1c)", "description": "Calculated as an estimate of the mean change in HbA1c after 16 weeks of treatment.", "populationDescription": "Intention-to-Treat analysis set (ITT) is all subjects who entered the trial treatment period and exposed to at least one dose of trial product.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage (%) of total haemoglobin", "timeFrame": "week -2 (screening), week 16", "groups": [{"id": "OG000", "title": "Repaglinide + Metformin", "description": "Initial dose of repaglinide 1mg plus metformin 500mg once daily. During the dose titration period of 6 weeks, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily."}, {"id": "OG001", "title": "Repaglinide", "description": "Initial dose of repaglinide 1 mg three times daily. During the dose titration period of 6 weeks, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg three times daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "212"}, {"groupId": "OG001", "value": "209"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-4.450", "spread": "0.070"}, {"groupId": "OG001", "value": "-4.148", "spread": "0.071"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The non-inferiority margin for HbA1c was set to 0.4%.\n\nThe null hypothesis (H0) was:\n\nH0: HbA1c of repaglinide + metformin therapy after 16 weeks of treatment - HbA1c of repaglinide monotherapy after 16 weeks of treatment \u22650.4%\n\nAgainst the alternative hypothesis (H1):\n\nH1: HbA1c of repaglinide + metformin therapy after 16 weeks of treatment - HbA1c of repaglinide monotherapy after 16 weeks of treatment \\<0.4%", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "If non-inferiority was shown (that was if H0 was rejected), then superiority of repaglinide and metformin combination therapy compared to repaglinide monotherapy would be claimed if the upper limit of the 95% CI for the difference was lower than 0%.\n\nThe non-inferiority margin for HbA1c was set to 0.4%.", "statisticalMethod": "ANCOVA", "paramType": "Estimated treatment difference, LS Mean", "paramValue": "-0.302", "ciPctValue": "95", "ciLowerLimit": "-0.491", "ciUpperLimit": "-0.114", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0096"}]}, {"type": "SECONDARY", "title": "Change in Fasting Plasma Glucose", "description": "Calculated as an estimate of the mean change in fasting plasma glucose after 16 weeks of treatment.", "populationDescription": "Intention-to-Treat analysis set (ITT) is all subjects who entered the trial treatment period and exposed to at least one dose of trial product.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "week 0, week 16", "groups": [{"id": "OG000", "title": "Repaglinide + Metformin", "description": "Initial dose of repaglinide 1mg plus metformin 500mg once daily. During the dose titration period of 6 weeks, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily."}, {"id": "OG001", "title": "Repaglinide", "description": "Initial dose of repaglinide 1 mg three times daily. During the dose titration period of 6 weeks, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg three times daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "211"}, {"groupId": "OG001", "value": "209"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-4.646", "spread": "0.129"}, {"groupId": "OG001", "value": "-3.982", "spread": "0.130"}]}]}]}, {"type": "SECONDARY", "title": "Change in 2-hour Postprandial Plasma Glucose", "description": "Calculated as an estimate of the mean change in 2-hour postprandial plasma glucose following a standard test meal after 16 weeks of treatment", "populationDescription": "Intention-to-Treat analysis set (ITT) is all subjects who entered the trial treatment period and exposed to at least one dose of trial product.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Repaglinide + Metformin", "description": "Initial dose of repaglinide 1mg plus metformin 500mg once daily. During the dose titration period of 6 weeks, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily."}, {"id": "OG001", "title": "Repaglinide", "description": "Initial dose of repaglinide 1 mg three times daily. During the dose titration period of 6 weeks, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg three times daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "210"}, {"groupId": "OG001", "value": "204"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-7.525", "spread": "0.237"}, {"groupId": "OG001", "value": "-6.794", "spread": "0.242"}]}]}]}, {"type": "SECONDARY", "title": "Change in 7-point Plasma Glucose Profile", "description": "Calculated as an estimate of the mean change in 7-point (before breakfast, 2 hours after breakfast, before lunch, 2 hours after lunch, before dinner, 2 hours after dinner, bedtime) plasma glucose profile after 16 weeks of treatment.", "populationDescription": "Intention-to-Treat analysis set (ITT) is all subjects who entered the trial treatment period and exposed to at least one dose of trial product.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Repaglinide + Metformin", "description": "Initial dose of repaglinide 1mg plus metformin 500mg once daily. During the dose titration period of 6 weeks, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily."}, {"id": "OG001", "title": "Repaglinide", "description": "Initial dose of repaglinide 1 mg three times daily. During the dose titration period of 6 weeks, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg three times daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "218"}, {"groupId": "OG001", "value": "214"}]}], "classes": [{"title": "Before breakfast, N=204, 199", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.99", "spread": "0.11"}, {"groupId": "OG001", "value": "-4.58", "spread": "0.12"}]}]}, {"title": "2 hours after breakfast, N=206, 201", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.85", "spread": "0.23"}, {"groupId": "OG001", "value": "-7.40", "spread": "0.24"}]}]}, {"title": "Before lunch, N=203, 200", "categories": [{"measurements": [{"groupId": "OG000", "value": "-6.85", "spread": "0.18"}, {"groupId": "OG001", "value": "-6.28", "spread": "0.18"}]}]}, {"title": "2 hours after lunch, N=204, 201", "categories": [{"measurements": [{"groupId": "OG000", "value": "-8.00", "spread": "0.21"}, {"groupId": "OG001", "value": "-6.98", "spread": "0.21"}]}]}, {"title": "Before dinner N=204, 202", "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.62", "spread": "0.17"}, {"groupId": "OG001", "value": "-5.09", "spread": "0.17"}]}]}, {"title": "2 hours after dinner N=204, 199", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.13", "spread": "0.21"}, {"groupId": "OG001", "value": "-5.70", "spread": "0.22"}]}]}, {"title": "Bedtime N=195, 188", "categories": [{"measurements": [{"groupId": "OG000", "value": "-6.93", "spread": "0.19"}, {"groupId": "OG001", "value": "-5.82", "spread": "0.19"}]}]}, {"title": "Average N=207, 202", "categories": [{"measurements": [{"groupId": "OG000", "value": "-6.78", "spread": "0.14"}, {"groupId": "OG001", "value": "-5.99", "spread": "0.14"}]}]}]}, {"type": "SECONDARY", "title": "Change in Fasting Serum Insulin", "description": "Calculated as an estimate of the mean change in fasting serum insulin after 16 weeks of treatment.", "populationDescription": "Intention-to-Treat analysis set (ITT) is all subjects who entered the trial treatment period and exposed to at least one dose of trial product. A total of 100 subjects (50 per study group) out of the total subjects were randomly selected in the trial. Four trial sites were selected for the subgroup study.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mU/L", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Repaglinide + Metformin", "description": "Initial dose of repaglinide 1mg plus metformin 500mg once daily. During the dose titration period of 6 weeks, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily."}, {"id": "OG001", "title": "Repaglinide", "description": "Initial dose of repaglinide 1 mg three times daily. During the dose titration period of 6 weeks, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg three times daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "46"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.163", "spread": "1.801"}, {"groupId": "OG001", "value": "5.694", "spread": "1.872"}]}]}]}, {"type": "SECONDARY", "title": "Change in 2-hour Postprandial Serum Insulin", "description": "Calculated as an estimate of the mean change in 2-hour postprandial serum insulin after 16 weeks of treatment.", "populationDescription": "Intention-to-Treat analysis set (ITT) is all subjects who entered the trial treatment period and exposed to at least one dose of trial product. A total of 100 subjects (50 per study group) out of the total subjects were randomly selected in the trial. Four trial sites were selected for the subgroup study.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mU/L", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Repaglinide + Metformin", "description": "Initial dose of repaglinide 1mg plus metformin 500mg once daily. During the dose titration period of 6 weeks, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily."}, {"id": "OG001", "title": "Repaglinide", "description": "Initial dose of repaglinide 1 mg three times daily. During the dose titration period of 6 weeks, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg three times daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "44"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "34.083", "spread": "6.731"}, {"groupId": "OG001", "value": "28.548", "spread": "7.132"}]}]}]}, {"type": "SECONDARY", "title": "Change in Fasting Serum C-peptide", "description": "Calculated as an estimate of the mean change in fasting serum C-peptide after 16 weeks of treatment", "populationDescription": "Intention-to-Treat analysis set (ITT) is all subjects who entered the trial treatment period and exposed to at least one dose of trial product. A total of 100 subjects (50 per study group) out of the total subjects were randomly selected in the trial. Four trial sites were selected for the subgroup study.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "ng/ml", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Repaglinide + Metformin", "description": "Initial dose of repaglinide 1mg plus metformin 500mg once daily. During the dose titration period of 6 weeks, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily."}, {"id": "OG001", "title": "Repaglinide", "description": "Initial dose of repaglinide 1 mg three times daily. During the dose titration period of 6 weeks, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg three times daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "46"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.041", "spread": "0.123"}, {"groupId": "OG001", "value": "0.405", "spread": "0.128"}]}]}]}, {"type": "SECONDARY", "title": "Change in 2-hour Postprandial Serum C-peptide", "description": "Calculated as an estimate of the mean change in 2-hour postprandial serum C-peptide after 16 weeks of treatment", "populationDescription": "Intention-to-Treat analysis set (ITT) is all subjects who entered the trial treatment period and exposed to at least one dose of trial product. A total of 100 subjects (50 per study group) out of the total subjects were randomly selected in the trial. Four trial sites were selected for the subgroup study.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "ng/ml", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Repaglinide + Metformin", "description": "Initial dose of repaglinide 1mg plus metformin 500mg once daily. During the dose titration period of 6 weeks, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily."}, {"id": "OG001", "title": "Repaglinide", "description": "Initial dose of repaglinide 1 mg three times daily. During the dose titration period of 6 weeks, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg three times daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "44"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.301", "spread": "0.347"}, {"groupId": "OG001", "value": "2.081", "spread": "0.369"}]}]}]}, {"type": "SECONDARY", "title": "Hypoglycaemic Episodes", "description": "Number of hypoglycaemic episodes from Week 0 to Week 16, defined as major, minor or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.", "populationDescription": "Safety analysis set was defined as all randomised and exposed subjects.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "episodes", "timeFrame": "Weeks 0-16", "groups": [{"id": "OG000", "title": "Repaglinide + Metformin", "description": "Initial dose of repaglinide 1mg plus metformin 500mg once daily. During the dose titration period of 6 weeks, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily."}, {"id": "OG001", "title": "Repaglinide", "description": "Initial dose of repaglinide 1 mg three times daily. During the dose titration period of 6 weeks, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg three times daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "218"}, {"groupId": "OG001", "value": "214"}]}], "classes": [{"title": "Major", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Minor", "categories": [{"measurements": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "16"}]}]}, {"title": "Symptoms only", "categories": [{"measurements": [{"groupId": "OG000", "value": "90"}, {"groupId": "OG001", "value": "71"}]}]}]}, {"type": "SECONDARY", "title": "Change in Blood Pressure", "description": "Calculated as the mean change in diastolic and systolic blood pressure after 16 weeks of treatment", "populationDescription": "Safety analysis set was defined as all randomised and exposed subjects.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Week 0, week 16", "groups": [{"id": "OG000", "title": "Repaglinide + Metformin", "description": "Initial dose of repaglinide 1mg plus metformin 500mg once daily. During the dose titration period of 6 weeks, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily."}, {"id": "OG001", "title": "Repaglinide", "description": "Initial dose of repaglinide 1 mg three times daily. During the dose titration period of 6 weeks, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg three times daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "196"}, {"groupId": "OG001", "value": "201"}]}], "classes": [{"title": "Blood pressure diastolic", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.0", "spread": "8.8"}, {"groupId": "OG001", "value": "-0.9", "spread": "9.5"}]}]}, {"title": "Blood pressure systolic", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.5", "spread": "14.3"}, {"groupId": "OG001", "value": "-1.4", "spread": "14.2"}]}]}]}, {"type": "SECONDARY", "title": "Physical Examinations", "description": "The number of subjects having a physical examination event that changed from 'Normal' or 'Abnormal, not clinically significant' to 'Abnormal, clinically significant'. Physical examination included cardiovascular system, respiratory system, musculoskeletal system, nervous system and abdomen.", "populationDescription": "Safety analysis set was defined as all randomised and exposed subjects.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Subjects", "timeFrame": "Week -2, week 16", "groups": [{"id": "OG000", "title": "Repaglinide + Metformin", "description": "Initial dose of repaglinide 1mg plus metformin 500mg once daily. During the dose titration period of 6 weeks, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily."}, {"id": "OG001", "title": "Repaglinide", "description": "Initial dose of repaglinide 1 mg three times daily. During the dose titration period of 6 weeks, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg three times daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "218"}, {"groupId": "OG001", "value": "214"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "ECG (ElectroCardioGram)", "description": "The number of subjects having a electrocardiogram (ECG) that changed from 'Normal' or 'Abnormal, not clinically significant' to 'Abnormal, clinically significant'. 'Abnormal, Clinically significant' is an abnormality that suggests a disease and/or organ toxicity and is of a severity, which requires active management.", "populationDescription": "Safety analysis set was defined as all randomised and exposed subjects.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Subjects", "timeFrame": "Week -2, week 16", "groups": [{"id": "OG000", "title": "Repaglinide + Metformin", "description": "Initial dose of repaglinide 1mg plus metformin 500mg once daily. During the dose titration period of 6 weeks, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily."}, {"id": "OG001", "title": "Repaglinide", "description": "Initial dose of repaglinide 1 mg three times daily. During the dose titration period of 6 weeks, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg three times daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "218"}, {"groupId": "OG001", "value": "214"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "2"}]}]}]}, {"type": "SECONDARY", "title": "Biochemistry: Alanine Aminotransferase (ALAT)", "description": "The number of subjects having a change in Alanine Aminotransferase (ALAT) from 'Normal' or 'Abnormal, not clinically significant' to 'Abnormal, clinically significant'. 'Abnormal, Clinically significant' is an abnormality that suggests a disease and/or organ toxicity and is of a severity, which requires active management.", "populationDescription": "Safety analysis set was defined as all randomised and exposed subjects.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Subjects", "timeFrame": "Week -2, week 16", "groups": [{"id": "OG000", "title": "Repaglinide + Metformin", "description": "Initial dose of repaglinide 1mg plus metformin 500mg once daily. During the dose titration period of 6 weeks, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily."}, {"id": "OG001", "title": "Repaglinide", "description": "Initial dose of repaglinide 1 mg three times daily. During the dose titration period of 6 weeks, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg three times daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "218"}, {"groupId": "OG001", "value": "214"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "5"}]}]}]}, {"type": "SECONDARY", "title": "Biochemistry: Alanine Aminotransferase (ASAT)", "description": "The number of subjects having a change in Aspartate Aminotransferase (ASAT) from 'Normal' or 'Abnormal, not clinically significant' to 'Abnormal, clinically significant'. 'Abnormal, Clinically significant' is an abnormality that suggests a disease and/or organ toxicity and is of a severity, which requires active management.", "populationDescription": "Safety analysis set was defined as all randomised and exposed subjects.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Subjects", "timeFrame": "Week -2, week 16", "groups": [{"id": "OG000", "title": "Repaglinide + Metformin", "description": "Initial dose of repaglinide 1mg plus metformin 500mg once daily. During the dose titration period of 6 weeks, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily."}, {"id": "OG001", "title": "Repaglinide", "description": "Initial dose of repaglinide 1 mg three times daily. During the dose titration period of 6 weeks, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg three times daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "218"}, {"groupId": "OG001", "value": "214"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "4"}]}]}]}, {"type": "SECONDARY", "title": "Haematology: Haemoglobin", "description": "Haemoglobin was measured. The number of subjects having a change in Haemoglobin measurement from 'Normal' or 'Abnormal, not clinically significant' to 'Abnormal, clinically significant' 'Abnormal, Clinically significant' is an abnormality that suggests a disease and/or organ toxicity and is of a severity, which requires active management.", "populationDescription": "Safety analysis set was defined as all randomised and exposed subjects.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Subjects", "timeFrame": "Week -2, week 16", "groups": [{"id": "OG000", "title": "Repaglinide + Metformin", "description": "Initial dose of repaglinide 1mg plus metformin 500mg once daily. During the dose titration period of 6 weeks, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily."}, {"id": "OG001", "title": "Repaglinide", "description": "Initial dose of repaglinide 1 mg three times daily. During the dose titration period of 6 weeks, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg three times daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "218"}, {"groupId": "OG001", "value": "214"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "The adverse events were collected in a time span of 16 weeks.", "description": "The safety analysis set contains all randomised subjects exposed to at least one dose of trial drug(s).", "eventGroups": [{"id": "EG000", "title": "Repaglinide + Metformin", "description": "Initial dose of repaglinide 1mg plus metformin 500mg once daily. During the dose titration period of 6 weeks, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily.", "seriousNumAffected": 0, "seriousNumAtRisk": 218, "otherNumAffected": 0, "otherNumAtRisk": 218}, {"id": "EG001", "title": "Repaglinide", "description": "Initial dose of repaglinide 1 mg three times daily. During the dose titration period of 6 weeks, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg three times daily.", "seriousNumAffected": 1, "seriousNumAtRisk": 214, "otherNumAffected": 0, "otherNumAtRisk": 214}], "seriousEvents": [{"term": "Anxiety", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 218}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 214}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Novo Nordisk reserves the right to not release data until specified milestones, e.g. when the clinical trial report is available. At the end of the trial, one or more manuscripts for publication will be prepared collaboratively between Investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for less than 60 days to protect intellectual property."}, "pointOfContact": {"title": "Public Access to Clinical Trials", "organization": "Novo Nordisk A/S", "email": "clinicaltrials@novonordisk.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000072379", "term": "Repaglinide"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M354161", "name": "Repaglinide", "asFound": "Voriconazole", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}